• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Bone Biopsy Market Analysis

    ID: MRFR/HC/3898-CR
    98 Pages
    Kinjoll Dey
    September 2022

    Bone Biopsy Market Research Report Information by Type (Needle Biopsy, Open Biopsy), by Guided (MRI-Guided and CT-Guided), by End User (Hospitals & Clinics, Surgical Centers, and Others), and by Region (North America, Europe, Asia-Pacific, and the Rest of the World)—Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Bone Biopsy Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Analysis

    In-depth Analysis of Bone Biopsy Market Industry Landscape

    A bone biopsy is a medical test that takes a small sample of tissue or cells from the bone to figure out if there's cancer or bone disease. More people getting bone cancer means more need for bone biopsy tests. The World Health Organization (WHO) says cancer is the main cause of death worldwide. According to the American Cancer Society, in 2022, there will be around 3,910 new cases and about 2,100 deaths from primary cancer of the bones and joints. The American Society of Clinical Oncology (ASCO) says in 2020, about 400 cases of primary bone sarcoma happened in people aged 15 to 19. In the UK, Cancer Research UK says there are about 550 new bone sarcoma cases every year. That's more than 1 case every day. This info shows that bone cancer cases are going up in different parts of the world. If bone cancer isn't found early, it can spread and cause many problems like broken bones, pain, or more serious issues. Bone biopsy is helpful in finding bone cancer in people before it spreads to other parts of the body. It's the best way to diagnose bone cancer. A sample of the affected bone is taken and sent to a lab for testing. Bone biopsy can tell exactly what type of bone cancer a patient has and what stage it's in. The increasing number of bone cancer cases is creating a demand for bone biopsy procedures, and that's boosting the global bone biopsy market.

    Bone biopsy is a medical test where a small sample of tissue or cells is taken from the bone to check for cancer or bone disease. More people getting bone cancer means there's a greater need for bone biopsy tests. According to the World Health Organization (WHO), cancer is the leading cause of death globally. The American Cancer Society predicts that in 2022, there will be approximately 3,910 new cases and about 2,100 deaths from primary cancer of the bones and joints. The American Society of Clinical Oncology (ASCO) notes that in 2020, around 400 cases of primary bone sarcoma occurred in people aged 15 to 19. Additionally, Cancer Research UK states that there are about 550 new bone sarcoma cases in the UK every year. This information indicates that bone cancer cases are on the rise worldwide. If not detected early, bone cancer can spread and lead to issues like broken bones, pain, or more serious complications. Bone biopsy is a valuable method for detecting bone cancer before it spreads to other parts of the body. It is the most definitive way to diagnose bone cancer, involving collecting a sample of the affected bone and sending it to a laboratory for testing. Bone biopsy can identify the exact type of bone cancer a patient has and determine the stage it's at. The increasing prevalence of bone cancer is driving the demand for bone biopsy procedures, contributing to the growth of the global bone biopsy market.

    A bone biopsy is a medical test that involves taking a small sample of tissue or cells from the bone to check for cancer or bone disease. With more people being diagnosed with bone cancer, there's a growing need for bone biopsy tests. The World Health Organization (WHO) states that cancer is the leading cause of death globally. According to the American Cancer Society, around 3,910 new cases and about 2,100 deaths from primary cancer of the bones and joints are expected in 2022. The American Society of Clinical Oncology (ASCO) reports that in 2020, there were approximately 400 cases of primary bone sarcoma in people aged 15 to 19. Additionally, Cancer Research UK mentions that there are about 550 new bone sarcoma cases in the UK every year. This information highlights the increasing number of bone cancer cases worldwide. If not detected early, bone cancer can spread and lead to complications like broken bones and severe pain. Bone biopsy is a crucial method for detecting bone cancer before it spreads. It is the most definitive way to diagnose bone cancer, involving the collection of a sample from the affected bone and sending it to a laboratory for testing. Bone biopsy can determine the precise type of bone cancer a patient has and its stage. The rising prevalence of bone cancer is generating a demand for bone biopsy procedures, contributing to the growth of the global bone biopsy market.

    A bone biopsy is a medical test where a small sample of tissue or cells is taken from the bone to check for cancer or bone disease. The increasing number of people diagnosed with bone cancer has led to a higher demand for bone biopsy tests. According to the World Health Organization (WHO), cancer is the main cause of death worldwide. The American Cancer Society predicts that in 2022, there will be approximately 3,910 new cases and about 2,100 deaths from primary cancer of the bones and joints. The American Society of Clinical Oncology (ASCO) notes that in 2020, around 400 cases of primary bone sarcoma occurred in people aged 15 to 19. Additionally, Cancer Research UK mentions that there are about 550 new bone sarcoma cases in the UK every year. These statistics indicate a growing number of bone cancer cases globally. If not detected early, bone cancer can spread and lead to complications like broken bones and severe pain. Bone biopsy is a critical method for detecting bone cancer before it spreads, involving the collection of a sample from the affected bone

    Market Summary

    The Global Bone Biopsy Market is projected to grow from 0.72 USD Billion in 2024 to 1.3 USD Billion by 2035, indicating robust growth potential.

    Key Market Trends & Highlights

    Global Bone Biopsy Key Trends and Highlights

    • The market is expected to achieve a compound annual growth rate (CAGR) of 5.54% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 1.3 USD Billion, reflecting increasing demand for bone biopsy procedures.
    • In 2024, the market is valued at 0.72 USD Billion, showcasing a solid foundation for future growth.
    • Growing adoption of advanced imaging technologies due to the rising prevalence of bone-related diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.72 (USD Billion)
    2035 Market Size 1.3 (USD Billion)
    CAGR (2025-2035) 5.54%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Argon Medical, Braun Melsungen, Becton, Dickinson, and Company, Cardinal Health, Inc., Mermaid Medical A / S, Kimal PLC, Stryker, Cook Group Incorporated, Remington Medical, Merit Medical Systems Inc.

    Market Trends

    DRIVERS Growing demand for minimally invasive procedures

    Growing demand for minimally invasive procedures is fuelling the growth of the global bone biopsy market. A minimally invasive procedure is the use of a variety of techniques to operate with less damage to the patient’s body. It has various benefits, such as fewer operative and post-operative major complications, less post-operative pain, shortened hospital stays, and faster recovery times. According to the WHO, in 2019, it was reported that around 235 million major surgeries are conducted every year across the globe.

    Bone biopsy is a minimally invasive procedure that becomes the initial procedure of choice in most cases for obtaining bone samples. It offers multiple advantages over open surgical biopsy, including minimal soft tissue injury, maintenance of a bone structure, and a reduced need for general anesthesia. This results in an increasing preference for minimally invasive procedures by patients. This is driving the global bone biopsy market

    Increasing acceptance of bone marrow biopsy for diagnosis and treatment of lymphoma and leukemia disease

    Restraints Stringent regulatory policies

    The stringent regulatory policies for manufacturing and distributing medical devices in various regions are hampering the growth of the global bone biopsy market. For instance, the US Food & Drug Administration (FDA)’s Center for Devices and Radiological Health (CDRH) regulates the manufacturing, repackaging, relabelling, and/or importing of medical devices sold in the US. The basic regulatory requirements that manufacturers of medical devices distributed in the U.S. must comply with are established registration, medical device listing, premarket notification 510 (k), quality system regulations, medical device reporting, and others.

    Both domestic and foreign manufacturers of medical devices must register their establishments with the FDA. This is a restraining factor for the players involved in the global bone biopsy market.

    Opportunities Improving healthcare infrastructure across emerging countries

    Improving healthcare infrastructure across emerging countries is creating opportunities for the players involved in the bone biopsy market. The growth of the healthcare infrastructure enhances the development of advanced products for bone biopsy procedures. The players involved in the healthcare sector across emerging countries are heavily investing in technologies. For instance, in May 2022, Terumo India, the Indian arm of Terumo Corporation, signed a partnership agreement with US-based Argon Medical, the market leader in specialty medical products, including guide wires, IVC filters & retrievals, bone & soft tissue biopsy needles, and other products in India.

    It will help Terumo to offer advanced medical solutions. The geriatric population is increasing in emerging countries such as China and India. For instance, according to WHO, in 2019, there were 254 million older people aged 60 and over, and 176 million older people aged 65 and over in China. Geriatric people are more susceptible to chronic diseases such as cancer, which is also fuelling the demand for advanced bone biopsy products in the region.

    Value Chain Analysis

    The global bone biopsy market is showing positive movements in growth owing to the increasing cases of blood and marrow diseases and growing incidences of bone cancer across the globe. The value chain analysis for the market comprises four major components, which start with the R&D designing, manufacturing, distribution & sales, and post-sales review.

    Bone biopsy needles and other products related to bone biopsy require extensive research and development to obtain accurate results. The scientific research and development of advanced and effective biopsy products have excelled in diagnosing bone marrow-related diseases among individuals. These products require years of investigation and product testing to get an efficient and accurate portfolio. R&D and designing of such products are focused on expanding their product range of new needles aimed at improving surgical procedures. In this process, the product strategies are ready, and the manufacturing process of the product commences.

    The manufacturing process begins with the assembling of raw materials and production of needles, and other products in-house or through third-party manufacturers. Distribution & sales is an essential part of any industry. The revenue of the bone biopsy market majorly depends on distribution and sales. This market consists of distribution & sales, which further includes intermediaries, direct selling, and others. A robust distribution network, strong customer base, and effective sales team drive the sales of bone biopsy consumables.

    As products in the market are developed for testing bone marrow problems, the development of abnormal cells and other bone problems are reviewed by government agencies, and their functions are monitored closely to minimize any side effects among the users. The products are also monitored to enhance the current functioning and eliminate the existing problems related to the side effects and other minor glitches.

    The increasing prevalence of bone-related diseases and advancements in biopsy techniques are driving a notable transformation in the bone biopsy market, suggesting a shift towards more precise and less invasive diagnostic procedures.

    U.S. National Institutes of Health (NIH)

    Bone Biopsy Market Market Drivers

    Market Growth Projections

    The Global Bone Biopsy Market Industry is projected to experience substantial growth over the next decade. With an estimated market value of 0.72 USD Billion in 2024, it is expected to reach 1.3 USD Billion by 2035. This growth trajectory indicates a compound annual growth rate (CAGR) of 5.54% from 2025 to 2035. Factors contributing to this growth include increasing incidences of bone disorders, advancements in biopsy technologies, and rising awareness of bone health. These projections suggest a promising future for the industry, driven by both technological and demographic trends.

    Expanding Applications in Oncology

    The Global Bone Biopsy Market Industry is witnessing an expansion in applications, particularly in oncology. Bone biopsies are increasingly utilized for diagnosing metastatic cancers and assessing treatment responses. As the global cancer burden rises, the need for accurate diagnostic tools becomes more critical. For example, bone metastases occur in approximately 70% of patients with advanced breast or prostate cancer, necessitating effective biopsy procedures. This trend indicates a growing market potential, as healthcare providers seek reliable methods for cancer diagnosis and management, further driving the industry's growth.

    Government Initiatives and Funding

    Government initiatives aimed at improving healthcare infrastructure and funding for diagnostic procedures are positively influencing the Global Bone Biopsy Market Industry. Various countries are investing in healthcare systems to enhance access to advanced diagnostic tools, including bone biopsies. For instance, national health programs that allocate funds for cancer diagnosis and treatment are likely to increase the availability of bone biopsy services. This support from governments may lead to a more robust market environment, facilitating growth and innovation within the industry.

    Increasing Incidence of Bone Disorders

    The Global Bone Biopsy Market Industry is experiencing growth driven by the rising prevalence of bone disorders such as osteoporosis and bone cancers. As populations age, the incidence of these conditions increases, necessitating diagnostic procedures like bone biopsies. For instance, osteoporosis affects approximately 200 million women worldwide, highlighting the need for effective diagnostic tools. This trend is expected to contribute to the market's expansion, with the industry projected to reach 0.72 USD Billion in 2024, indicating a growing demand for bone biopsy procedures.

    Rising Awareness and Screening Programs

    Growing awareness regarding bone health and the importance of early diagnosis is propelling the Global Bone Biopsy Market Industry. Public health initiatives and screening programs aimed at detecting bone-related diseases are becoming more prevalent. For instance, campaigns promoting osteoporosis screening have led to increased patient referrals for bone biopsies. This heightened awareness is likely to drive demand for diagnostic procedures, contributing to the market's growth trajectory. By 2035, the industry is projected to reach 1.3 USD Billion, underscoring the impact of awareness on the adoption of bone biopsy techniques.

    Technological Advancements in Biopsy Techniques

    Innovations in biopsy techniques are significantly influencing the Global Bone Biopsy Market Industry. The introduction of minimally invasive procedures and advanced imaging technologies enhances the accuracy and safety of bone biopsies. For example, the use of ultrasound-guided biopsies allows for real-time imaging, improving the precision of needle placement. These advancements not only improve patient outcomes but also increase the efficiency of the procedures, potentially leading to a higher adoption rate. As a result, the market is anticipated to grow at a CAGR of 5.54% from 2025 to 2035, reflecting the positive impact of technology on the industry.

    Market Segment Insights

    Bone Biopsy Type Insights

    Needle biopsies are majorly performed for the better assessment of bone cancer within an outpatient setting. The need for highly skilled operators to handle imaging modalities like CT scans and the lower technical complexities involved in this method are driving the demand for a needle biopsy to extract normal bone tissues for biopsy.

    An open biopsy is a surgical procedure wherein an incision is made through the skin for exposing the tumor and allowing the tissue sample to be cut or scraped away. An open biopsy can be categorized as either incisional (the tumor capsule is intentionally violated as part of the procedure, and a portion of the mass or lesion is removed) or excisional (the entire tumor is removed).

    Bone Biopsy Guided Insights

    Biopsy under MRI guidance is especially valuable for the localization of bone marrow lesions, lesions that cannot be visualized using CT, and viable tumors (after chemotherapy or radiation). In addition, MRI-guided bone biopsy is accurate, safe, a better alternative biopsy method, and is a good adjunctive technique for the localization of bone lesions for radiofrequency ablation or other interventional procedures.

    Computed tomography (CT)-guided bone biopsy is a diagnostic procedure for obtaining a tissue sample with a high diagnostic yield and low complications. CT-guided biopsy combines a CT scan with a biopsy and uses images generated by a CT scanner (also called a cat scan) to accurately insert a needle into the suspect bone, allowing a sample to be removed for testing.

    Bone biopsy is performed as an outpatient procedure in the hospital that normally takes less than 60 minutes and hospitals are one of the first contact points and the most trustable option for the patients. The growing incidence and prevalence of cancer, rising demand for minimally invasive procedures, and large geriatric patient population is driving the demand for bone biopsy.

    The growing incidence of bone-related cancers coupled with the emergence of multiple detection approaches, including those involving advanced imaging techniques is driving the demand for bone biopsy in surgical centers. Bone biopsy is performed under the guidance of a variety of imaging modalities including computed tomography (CT) and magnetic resonance imaging (MRI). Benefits associated with the adoption of image-guidance biopsy in surgical centers such as avoidance of overnight hospital stay, earlier commencement of radiation therapy, cost & time saving, and biopsy of surgically inaccessible sites,

    Other segments include diagnostic centers. Bone biopsies are conducted by diagnostic centers to facilitate definitive pathological diagnoses while minimizing complications, limiting potential tumor seeding, and avoiding interference with subsequent therapies. A rise in the demand for minimally invasive techniques which causes less pain is driving the segment growth.

    Get more detailed insights about Bone Biopsy Market Research Report - Global Forecast till 2032

    Regional Insights

    Key Companies in the Bone Biopsy Market market include

    Industry Developments

      • In May 2022, Argon Medical partnered with Terumo India to provide medical products including guide wires, IVC filters and retrievals, bone and soft tissue biopsy needles, and other products in India. This gives an opportunity for Argon Medical to expand its product portfolio.
      • In April 2018, Merit Medical Systems launched Madison and Huntington Bone Biopsy Systems. The Madison product features include a trocar-tip stylet that can be created through the cannula to support initial bone entry. The Huntington is designed with a tri-angled tip and longitudinal groove that both provides accuracy even in diagonal approaches and functions as a collection channel for tissue evacuation upon first contact in hard bone procedures and sclerotic lesions.

    Future Outlook

    Bone Biopsy Market Future Outlook

    The Global Bone Biopsy Market is projected to grow at a 5.54% CAGR from 2024 to 2035, driven by technological advancements, increasing cancer prevalence, and rising demand for minimally invasive procedures.

    New opportunities lie in:

    • Develop innovative biopsy devices incorporating AI for enhanced accuracy and efficiency.
    • Expand market presence in emerging economies through strategic partnerships and localized manufacturing.
    • Invest in training programs for healthcare professionals to improve biopsy techniques and patient outcomes.

    By 2035, the Global Bone Biopsy Market is expected to achieve substantial growth, reflecting advancements in technology and increased healthcare investments.

    Market Segmentation

    Bone Biopsy Type Outlook

    • Needle Biopsy
    • Open Biopsy

    Bone Biopsy Guided Outlook

    • MRI-Guided
    • CT-Guided

    Bone Biopsy Region Outlook

    • North AmericaUS Canada
    • US
    • Canada
    • EuropeGermany France UK Italy Spain Rest of Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
    • Asia-PacificChina Japan India Australia South Korea Rest of Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & AfricaMiddle East Africa Latin America
    • Middle East
    • Africa
    • Latin America

    Bone Biopsy End User Outlook

    • Hospitals and Clinics
    • Surgical Centers
    • Others

    Report Scope

    Attribute/Metric Details
      Market Size 2023   USD 0.68 Billion
      Market Size 2024   USD 0.72 Billion
      Market Size 2032   USD 1.11 Billion
      CAGR   5.49% (2024-2032)
      Base Year   2023
      Forecast Period   2024-2032
      Historical Data   2018-2020
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Guided, End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World
      Key Vendors   Argon Medical (US), B. Braun Melsungen (Germany), Becton, Dickinson, and Company (US), Cardinal Health, Inc. (US), Mermaid Medical A / S (Denmark), Kimal PLC (UK), Stryker (US), Cook Group Incorporated (US), Remington Medical (Denmark), and Merit Medical Systems Inc. (US)
      Key Market Opportunities   Improving healthcare infrastructure across emerging countries
      Key Market Drivers   Increasing prevalence of bone cancers, growing demand for minimally invasive procedures, and increasing acceptance of bone marrow biopsy for diagnosis & treatment of lymphoma & leukemia disease

    Market Highlights

    Author

    Kinjoll Dey
    Research Analyst Level I

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    What is the expected growth rate of the global bone biopsy market?

    Global bone biopsy market is expected to expand at 5.49% CAGR from 2024-2032.

    What is the valuation of the global bone biopsy market?

    bone biopsy market can touch USD 1.11 Billion by 2032.

    What is the major driver of the global bone biopsy market?

    Rising prevalence of bone cancer is the primary driver of the global bone biopsy market.

    What is the restraining factor of the global bone biopsy market?

    Recall of products and strict regulatory policies are factors expected to impede the global gastric bypass market growth.

    Which region can dominate in the global bone biopsy market?

    The Americas is expected to dominate in the global bone biopsy market till 2032 due to high prevalence of bone cancer.

    Who are the prominent players of the global bone biopsy market?

    GENERAL ELECTRIC COMPANY, Cook, Kimal, Remington Medical, ARGON MEDICAL, BD, B. Braun Melsungen AG, Ranfac Corp., and MERMAID MEDICAL A/S are prominent players of the global bone biopsy market.

    1. LIST OF CONTENTS
    2. Executive Summary
    3. Market Introduction
      1. DEFINITION
      2. Scope of the Study
      3. RESEARCH OBJECTIVE
      4. MARKET STRUCTURE
      5. ASSUMPTIONS & LIMITATIONS
    4. Research Methodology
      1. DATA MINING
      2. SECONDARY RESEARCH
      3. PRIMARY RESEARCH
      4. BREAKDOWN OF PRIMARY RESPONDENTS
      5. FORECASTING TECHNIQUES
      6. Research Methodology FOR MARKET SIZE ESTIMATION
        1. Bottom-up Approach
        2. TOP-DOWN APPROACH
      7. DATA TRIANGULATION
      8. VALIDATION
    5. MARKET DYNAMICS
      1. OVERVIEW
      2. DRIVERS
        1. INCREASING PREVALENCE OF BONE CANCER
        2. GROWING DEMAND FOR MINIMALLY INVASIVE PROCEDURES
        3. INCREASING ACCEPTANCE OF BONE MARROW BIOPSY FOR DIAGNOSIS AND TREATMENT OF LYMPHOMA AND LEUKEMIA DISEASE
      3. RESTRAINTS
      4. OPPORTUNITIES
        1. IMPROVING HEALTHCARE INFRASTRUCTURE ACROSS EMERGING COUNTRIES
    6. MARKET FACTOR ANALYSIS
      1. VALUE CHAIN ANALYSIS
        1. R&D AND DESIGNING
        2. MANUFACTURING
        3. DISTRIBUTION & SALES
        4. POST-SALES REVIEW
      2. PORTER''S FIVE FORCES MODEL
        1. BARGAINING POWER OF BUYERS
        2. BARGAINING POWER OF SUPPLIERS
        3. THREAT OF NEW ENTRANTS
        4. THREAT OF SUBSTITUTES
        5. INTENSITY OF RIVALRY
      3. IMPACT OF COVID-19
        1. IMPACT ON DEMAND
        2. IMPACT ON SUPPLY CHAIN
    7. GLOBAL BONE BIOPSY MARKET, BY TYPE
      1. OVERVIEW
      2. NEEDLE BIOPSY
      3. OPEN BIOPSY
    8. GLOBAL BONE BIOPSY MARKET, BY GUIDED
      1. OVERVIEW
      2. MRI-GUIDED
      3. CT-GUIDED
    9. GLOBAL BONE BIOPSY MARKET, BY END USER
      1. OVERVIEW
      2. HOSPITALS AND CLINICS
      3. SURGICAL CENTERS
      4. OTHERS
    10. GLOBAL BONE BIOPSY MARKET, BY REGION
      1. OVERVIEW
      2. NORTH AMERICA
        1. US
        2. CANADA
      3. EUROPE
        1. GERMANY
        2. UK
        3. FRANCE
        4. ITALY
        5. SPAIN
        6. REST OF EUROPE
      4. ASIA-PACIFIC
        1. JAPAN
        2. CHINA
        3. INDIA
        4. AUSTRALIA
        5. SOUTH KOREA
        6. REST OF ASIA-PACIFIC
      5. REST OF THE WORLD
        1. MIDDLE EAST
        2. AFRICA
        3. LATIN AMERICA
    11. Competitive Landscape
      1. OVERVIEW
      2. COMPETITIVE BENCHMARKING
      3. MAJOR GROWTH STRATEGY IN THE GLOBAL BONE BIOPSY MARKET
      4. THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL BONE BIOPSY MARKET
      5. KEY DEVELOPMENT ANALYSIS
      6. KEY DEVELOPMENTS & GROWTH STRATEGIES
        1. PRODUCT LAUNCH/PRODUCT APPROVAL
        2. PARTNERSHIP/COLLABORATION
      7. MAJOR PLAYERS FINANCIAL MATRIX
        1. SALES 2021
        2. R&D EXPENDITURE (USD MILLION), 2021
      8. ARGON MEDICAL
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      9. B. BRAUN MELSUNGEN AG
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      10. BECTON, DICKINSON, AND COMPANY
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      11. CARDINAL HEALTH
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      12. MERMAID MEDICAL GROUP
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
      13. KIMAL PLC
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
      14. STRYKER
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      15. COOK MEDICAL
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS/S OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      16. REMINGTON MEDICAL
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
      17. MERIT MEDICAL SYSTEMS
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
    12. APPENDIX
      1. REFERENCES
      2. RELATED REPORTS
    13. List of Tables and Figures
      1. LIST OF TABLES
      2. TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
      3. TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
      4. TABLE 3 GLOBAL BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      5. TABLE 4 GLOBAL BONE BIOPSY MARKET, FOR NEEDLE BIOPSY, BY REGION, 2018–2030 (USD MILLION)
      6. TABLE 5 GLOBAL BONE BIOPSY MARKET, FOR OPEN BIOPSY, BY REGION, 2018–2030 (USD MILLION)
      7. TABLE 6 GLOBAL BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      8. TABLE 7 GLOBAL BONE BIOPSY MARKET, FOR MRI-GUIDED, BY REGION, 2018–2030 (USD MILLION)
      9. TABLE 8 GLOBAL BONE BIOPSY MARKET, FOR CT-GUIDED, BY REGION, 2018–2030 (USD MILLION)
      10. TABLE 9 GLOBAL BONE BIOPSY MARKET, BY END USER 2018–2030 (USD MILLION)
      11. TABLE 10 GLOBAL BONE BIOPSY MARKET, FOR HOSPITALS AND CLINICS, BY REGION, 2018–2030 (USD MILLION)
      12. TABLE 11 GLOBAL BONE BIOPSY MARKET, FOR SURGICAL CENTERS, BY REGION, 2018–2030 (USD MILLION)
      13. TABLE 12 GLOBAL BONE BIOPSY MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)
      14. TABLE 13 GLOBAL: BONE BIOPSY MARKET, BY REGION, 2018-2030 (USD MILLION)
      15. TABLE 14 NORTH AMERICA: BONE BIOPSY MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
      16. TABLE 15 NORTH AMERICA: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      17. TABLE 16 NORTH AMERICA: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      18. TABLE 17 NORTH AMERICA: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      19. TABLE 18 US: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      20. TABLE 19 US: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      21. TABLE 20 US : BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      22. TABLE 21 CANADA: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      23. TABLE 22 CANADA: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      24. TABLE 23 CANADA: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      25. TABLE 24 EUROPE: BONE BIOPSY MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
      26. TABLE 25 EUROPE: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      27. TABLE 26 EUROPE: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      28. TABLE 27 EUROPE: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      29. TABLE 28 GERMANY: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      30. TABLE 29 GERMANY: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      31. TABLE 30 GERMANY: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      32. TABLE 31 UK: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      33. TABLE 32 UK: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      34. TABLE 33 UK: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      35. TABLE 34 FRANCE: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      36. TABLE 35 FRANCE: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      37. TABLE 36 FRANCE: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      38. TABLE 37 ITALY: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      39. TABLE 38 ITALY: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      40. TABLE 39 ITALY: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      41. TABLE 40 SPAIN: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      42. TABLE 41 SPAIN: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      43. TABLE 42 SPAIN: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      44. TABLE 43 REST OF EUROPE: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      45. TABLE 44 REST OF EUROPE: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      46. TABLE 45 REST OF EUROPE: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      47. TABLE 46 ASIA-PACIFIC: BONE BIOPSY MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
      48. TABLE 47 ASIA-PACIFIC: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      49. TABLE 48 ASIA-PACIFIC: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      50. TABLE 49 ASIA-PACIFIC: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      51. TABLE 50 JAPAN: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      52. TABLE 51 JAPAN: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      53. TABLE 52 JAPAN: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      54. TABLE 53 CHINA: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      55. TABLE 54 CHINA: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      56. TABLE 55 CHINA: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      57. TABLE 56 INDIA: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      58. TABLE 57 INDIA: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      59. TABLE 58 INDIA: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      60. TABLE 59 AUSTRALIA: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      61. TABLE 60 AUSTRALIA: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      62. TABLE 61 AUSTRALIA: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      63. TABLE 62 SOUTH KOREA: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      64. TABLE 63 SOUTH KOREA: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      65. TABLE 64 SOUTH KOREA: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      66. TABLE 65 REST OF ASIA-PACIFIC: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      67. TABLE 66 REST OF ASIA-PACIFIC: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      68. TABLE 67 REST OF ASIA-PACIFIC: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      69. TABLE 68 REST OF THE WORLD: BONE BIOPSY MARKET, BY REGION, 2018-2030 (USD MILLION)
      70. TABLE 69 REST OF THE WORLD: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      71. TABLE 70 REST OF THE WORLD: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      72. TABLE 71 REST OF THE WORLD: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      73. TABLE 72 MIDDLE EAST: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      74. TABLE 73 MIDDLE EAST: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      75. TABLE 74 MIDDLE EAST: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      76. TABLE 75 AFRICA: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      77. TABLE 76 AFRICA: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      78. TABLE 77 AFRICA: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      79. TABLE 78 LATIN AMERICA: BONE BIOPSY MARKET, BY TYPE, 2018–2030 (USD MILLION)
      80. TABLE 79 LATIN AMERICA: BONE BIOPSY MARKET, BY GUIDED, 2018–2030 (USD MILLION)
      81. TABLE 80 LATIN AMERICA: BONE BIOPSY MARKET, BY END USER, 2018–2030 (USD MILLION)
      82. TABLE 81 MAJOR PLAYERS IN THE GLOBAL BONE BIOPSY MARKET
      83. TABLE 82 MOST ACTIVE PLAYERS IN THE GLOBAL BONE BIOPSY MARKET
      84. TABLE 83 PRODUCT LAUNCH/PRODUCT APPROVAL
      85. TABLE 84 PARTNERSHIP/COLLABORATION
      86. TABLE 85 ARGON MEDICAL: PRODUCTS OFFERED
      87. TABLE 86 ARGON MEDICAL: KEY DEVELOPMENTS
      88. TABLE 87 B. BRAUN MELSUNGEN AG: PRODUCTS OFFERED
      89. TABLE 88 BECTON, DICKINSON, AND COMPANY: PRODUCTS OFFERED
      90. TABLE 89 CARDINAL HEALTH: PRODUCTS OFFERED
      91. TABLE 90 MERMAID MEDICAL GROUP: PRODUCTS OFFERED
      92. TABLE 91 KIMAL PLC: PRODUCTS OFFERED
      93. TABLE 92 STRYKER: PRODUCTS OFFERED
      94. TABLE 93 COOK: PRODUCTS/ OFFERED
      95. TABLE 94 REMINGTON MEDICAL: PRODUCTSOFFERED
      96. TABLE 95 MERIT MEDICAL SYSTEMS: PRODUCTS OFFERED
      97. TABLE 96 MERIT MEDICAL SYSTEMS: KEY DEVELOPMENTS   LIST OF FIGURES
      98. FIGURE 1 MARKET SYNOPSIS
      99. FIGURE 2 GLOBAL BONE BIOPSY MARKET
      100. FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
      101. FIGURE 4 MARKET DYNAMICS: GLOBAL BONE BIOPSY MARKET
      102. FIGURE 5 DRIVERS: IMPACT ANALYSIS
      103. FIGURE 6 RESTRAINT: IMPACT ANALYSIS
      104. FIGURE 7 VALUE CHAIN: GLOBAL BONE BIOPSY MARKET
      105. FIGURE 8 PORTER''S FIVE FORCES ANALYSIS: GLOBAL BONE BIOPSY MARKET
      106. FIGURE 9 GLOBAL BONE BIOPSY MARKET, BY TYPE, 2021 & 2030 (USD MILLION)
      107. FIGURE 10 GLOBAL BONE BIOPSY MARKET SHARE, BY TYPE, 2021 (%)
      108. FIGURE 11 GLOBAL BONE BIOPSY MARKET, BY GUIDED, 2021 & 2030 (USD MILLION)
      109. FIGURE 12 GLOBAL BONE BIOPSY MARKET SHARE, BY GUIDED, 2021 (%)
      110. FIGURE 13 GLOBAL BONE BIOPSY MARKET, BY END USER, 2021 & 2030 (USD MILLION)
      111. FIGURE 14 GLOBAL BONE BIOPSY MARKET SHARE, BY END USER, 2021 (%)
      112. FIGURE 15 GLOBAL: BONE BIOPSY MARKET, BY REGION 2021 & 2030 (USD MILLION)
      113. FIGURE 16 GLOBAL: BONE BIOPSY MARKET SHARE (%), BY REGION, 2021
      114. FIGURE 17 NORTH AMERICA: BONE BIOPSY MARKET SHARE (%), BY COUNTRY, 2021
      115. FIGURE 18 EUROPE: BONE BIOPSY MARKET SHARE (%), BY COUNTRY, 2021
      116. FIGURE 19 ASIA-PACIFIC: BONE BIOPSY MARKET SHARE (%), BY COUNTRY, 2021
      117. FIGURE 20 REST OF THE WORLD: BONE BIOPSY MARKET SHARE (%), BY COUNTRY, 2021
      118. FIGURE 21 BENCHMARKING OF MAJOR COMPETITORS
      119. FIGURE 22 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL BONE BIOPSY MARKET
      120. FIGURE 23 GLOBAL BONE BIOPSY MARKET: Competitive Landscape
      121. FIGURE 24 SALES 2021
      122. FIGURE 25 R&D EXPENDITURE (USD MILLION), 2021
      123. FIGURE 26 ARGON MEDICAL: SWOT ANALYSIS
      124. FIGURE 27 B. BRAUN MELSUNGEN AG: FINANCIAL OVERVIEW SNAPSHOT
      125. FIGURE 28 B. BRAUN MELSUNGEN AG: SWOT ANALYSIS

    Bone Biopsy Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials